

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28United States District Court
Northern District of California

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE eHEALTH, INC. SECURITIES
LITIGATION

Case No. 20-cv-02395-JST

**ORDER GRANTING MOTIONS FOR
JUDGMENT ON THE PLEADINGS**

Re: ECF Nos. 117, 119

Before the Court are motions for judgment on the pleadings filed by Defendants eHealth, Inc, Scott N. Flanders, and Derek N. Yung (collectively “eHealth Defendants”), ECF No. 117; and Defendant David K. Francis, ECF No. 119. The Court will grant the motions.

I. BACKGROUND¹

Lead Plaintiff Chicago & Vicinity Laborers’ District Council Pension Fund brings this proposed securities class action on behalf of all persons and entities who purchased or otherwise acquired shares of eHealth common stock between March 19, 2018, and July 23, 2020 (“Class Period”). ECF Nos. 46, 116. Plaintiff alleges that eHealth and its officers Flanders, Yung, and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making misleading statements during earnings calls that artificially inflated the price of eHealth stock during the Class Period.

eHealth is a health insurance broker that receives commissions from insurance companies

¹ For the purposes of deciding this motion, the Court accepts as true all allegations set forth in the operative amended complaint, ECF No. 46. *See Chavez v. United States*, 683 F.3d 1102, 1108 (9th Cir. 2012) (“[U]nder Rule 12(c) . . . ‘a court must determine whether the facts alleged in the complaint, taken as true, entitle the plaintiff to a legal remedy.’”) (quoting *Brooks v. Dunlop Mfg. Inc.*, No. 10-cv-4341-CRB, 2011 WL 6140912, at *3 (N.D. Cal. Dec. 9, 2011)).

1 for policies it sells on their behalf. A customer applies for a policy through eHealth; to become
2 effective, the insurance company must approve it. Once approved, eHealth begins to receive
3 commissions from the insurance company, but the policy can be cancelled by the member at any
4 time.

5 The earnings that eHealth reports to investors are based on the commissions that eHealth
6 anticipates it will receive from insurance companies for each policy. Prior to 2018, eHealth
7 “recognized revenue equal to only the commission received (or to be received) for the year in
8 which the applicant was approved” by the insurer. *Id.* ¶¶ 28-29. eHealth’s revenue-recognition
9 practices changed on January 1, 2018, when eHealth adopted a new accounting standard for
10 recognizing revenue, Accounting Standard Codification 606 (“ASC 606”), pursuant to which
11 eHealth recognized the entirety of the commissions it expected to receive over the expected life of
12 the policy, which it estimated to be three years.

13 Plaintiff alleges that eHealth overstated its earnings during the Class Period. Specifically,
14 Plaintiff alleges that eHealth’s officers made materially misleading statements regarding eHealth’s
15 expected earnings by concealing information about the costs it would need to incur to provide
16 customer care to retain existing members.² On earnings calls held on April 26, 2018, and
17 February 20, 2020, Flanders and Yung made statements which “left investors with the false
18 impression that the commissions” earned from health insurance companies “were free of
19 associated costs,” “depriv[ing investors] of the ability to adequately evaluate eHealth’s
20 profitability and assess the true risks associated with purchasing eHealth common stock.” *Id.*
21 ¶¶ 76, 93. These statements artificially inflated the price of eHealth stock by leading investors “to
22 believe that eHealth had stronger earnings potential than it truly did.” *Id.* ¶ 46. Defendants
23 capitalized on the artificially inflated stock price, selling over \$40 million of eHealth stock and
24 receiving more than \$15 million in equity compensation.

25 On April 8, 2020, research firm Muddy Waters Capital published a report stating that
26 eHealth’s “highly aggressive accounting masks [] a significantly unprofitable business,”

27

28 ² While Plaintiff initially challenged a broader set of statements as false or misleading; the majority of those statements were dismissed by the Court on August 12, 2021. *See* ECF No. 64.

1 overstating revenue and operating profit while understating a significant operating loss. *Id.* ¶ 6.
2 The release of the Muddy Waters report resulted in a sharp decline in the price of eHealth’s stock.
3 *Id.* On July 23, 2020, eHealth announced its earnings results for the second quarter of 2020,
4 which “confirmed” various aspects of the Muddy Waters report. *Id.* ¶¶ 64-65. The company’s
5 stock price fell again following release of these earnings results.

6 Plaintiff alleges that proposed class members were injured by Defendants’ misleading
7 statements because class members purchased eHealth stock when its price was artificially inflated
8 and incurred losses when the market learned the truth about eHealth’s financial condition.

9 On August 12, 2021, the Court granted in part Defendants’ motion to dismiss. ECF
10 No. 64. Defendants now move for judgment on the pleadings. ECF Nos. 117, 119.

11 **II. JURISDICTION**

12 The Court has jurisdiction under 28 U.S.C. § 1331.

13 **III. LEGAL STANDARD**

14 After the pleadings are closed—but early enough not to delay trial—a party may move for
15 judgment on the pleadings. Fed. R. Civ. P. 12(c). “Judgment on the pleadings is properly granted
16 when there is no issue of material fact in dispute, and the moving party is entitled to judgment as a
17 matter of law.” *Fleming v. Pickard*, 581 F.3d 922, 925 (9th Cir. 2009). For the purposes of a Rule
18 12(c) motion, courts “accept all factual allegations in the complaint as true and construe them in
19 the light most favorable to the non-moving party.” *Id.* Courts must consider the “complaint in its
20 entirety,” as well as “documents incorporated into the complaint by reference[] and matters of
21 which a court may take judicial notice.” *Webb v. Trader Joe’s Co.*, 999 F.3d 1196, 1201 (9th Cir.
22 2021) (quoting *Tellabs, Inc. v. Makor Issues & Rts., Ltd.*, 551 U.S. 308, 322 (2007)).

23 “Securities fraud class actions must meet the higher, exacting pleading standards of
24 Federal Rule of Civil Procedure 9(b) and the Private Securities Litigation Reform Act”
25 (“PSLRA”). *Or. Pub. Emps. Ret. Fund v. Apollo Grp. Inc.*, 774 F.3d 598, 604 (9th Cir. 2014).
26 Under Rule 9(b) and the PSLRA, a complaint must “state with particularity the circumstances
27 constituting fraud or mistake” and “state with particularity facts giving rise to a strong inference
28 that the defendant acted with the required state of mind” in making the false or misleading

1 statements. Fed. R. Civ. P. 9(b); 15 U.S.C. § 78u-4(b)(2)(A). Granting judgment on the pleadings
2 is appropriate where a complaint fails to satisfy the pleading standards of the PSLRA. *Heliotrope*
3 *Gen., Inc. v. Ford Motor Co.*, 189 F.3d 971, 980 (9th Cir. 1999).

4 **IV. INCORPORATION BY REFERENCE AND JUDICIAL NOTICE**

5 The eHealth Defendants request that the Court find incorporated by reference or judicially
6 notice transcripts of eHealth’s April 26, 2018 and February 20, 2020 earnings calls; press releases
7 filed with the Securities and Exchange Commission (“SEC”) on April 28, 2018, and February 20,
8 2020; 10-K forms filed with the SEC for the years ending December 31, 2017 and December 31,
9 2018; a 10-Q form filed with the SEC for the quarter ending September 30, 2019; and the April 8,
10 2020 Muddy Waters report. ECF No. 118. Plaintiff does not oppose this request.

11 **A. Incorporation by Reference**

12 A document is properly incorporated by reference where the complaint “refers extensively
13 to the document or the document forms the basis of the plaintiff’s claim.” *Khoja v. Orexigen*
14 *Therapeutics, Inc.*, 899 F.3d 988, 1002 (9th Cir. 2018) (quoting *United States v. Ritchie*, 342 F.3d
15 903, 907 (9th Cir. 2003)). “For ‘extensively’ to mean anything . . . it should, ordinarily at least,
16 mean more than once.” *Id.* at 1003. “[T]he mere mention of the existence of a document is
17 insufficient to incorporate [its] contents.” *Coto Settlement v. Eisenberg*, 593 F.3d 1031, 1038 (9th
18 Cir. 2010). Courts may assume the contents of incorporated documents are true, though not for
19 the sole purpose of disputing facts in a well-pleaded complaint. *Khoja*, 899 F.3d at 1003.

20 The transcripts of the April 26, 2018 and February 20, 2020 earnings calls are properly
21 incorporated by reference because Plaintiff challenges statements made on those calls as
22 misleading, such that the calls form the basis of Plaintiff’s claims. The Muddy Waters report is
23 extensively referred to—and excerpted—in the amended complaint, such that it is properly
24 incorporated by reference. The 10-Ks filed for 2017 and 2018 are also repeatedly referred to and
25 quoted in the complaint, such that they are properly incorporated by reference.

26 eHealth’s press releases, however, are not incorporated by reference into the amended
27 complaint. Defendants argue that the amended complaint refers extensively to the press releases,
28 citing two paragraphs which mention press releases. ECF No. 46 ¶ 17 (“The Individual

1 Defendants . . . possessed the power and authority to control the contents of the Company’s . . .
2 press releases.”); *id.* ¶ 148 (“[T]he market for eHealth common stock was an efficient market . . .
3 [because] eHealth . . . communicated . . . through regular disseminations of press releases.”). A
4 document is incorporated by reference if the complaint “refers extensively to *the document*.”
5 *Khoja*, 899 F.3d at 1002 (emphasis added). That a complaint includes two generic references to a
6 category of documents, without more, is insufficient to incorporate specific documents within that
7 category by reference.

8 **B. Judicial Notice**

9 Courts may judicially notice an adjudicative fact if it is “not subject to reasonable dispute”
10 because it is “generally known” or “can be accurately and readily determined from sources whose
11 accuracy cannot reasonably be questioned.” Fed. R. Evid. 201(b)(1)-(2). “Accordingly, ‘[a] court
12 may take judicial notice of matters of public record without converting a motion to dismiss into a
13 motion for summary judgment[,]’” “[b]ut a court cannot take judicial notice of disputed facts
14 contained in such public records.” *Khoja*, 899 F.3d at 999 (quoting *Lee v. City of Los Angeles*,
15 250 F.3d 668, 689 (9th Cir. 2001)).

16 Defendants request that this Court judicially notice the press releases and eHealth’s 10-Q
17 for the fact that eHealth made specific public disclosures regarding operating expenses, customer
18 care expenses, and adherence to policies under ASC 606. ECF No. 118 at 6. The Court may take
19 judicial notice of these documents, which were filed publicly with the SEC, to determine what
20 representations eHealth made to the market. *See In re Pivotal Sec. Litig.*, No. 19-cv-03589-CRB,
21 2020 WL 4193384, at *5 (N.D. Cal. July 21, 2020) (taking judicial notice of SEC filings to
22 determine what the defendant disclosed to the market).

23 **V. DISCUSSION**

24 **A. eHealth Defendants’ Motion for Judgment on the Pleadings**

25 **1. Section 10(b) and Rule 10b-5 Claims**

26 “To plead a claim under [S]ection 10(b) and Rule 10b-5, the Plaintiff must allege: (1) a
27 material misrepresentation or omission; (2) scienter; (3) a connection between the
28 misrepresentation or omission and the purchase or sale of a security; (4) reliance; (5) economic

1 loss; and (6) loss causation.” *Or. Pub. Emps. Ret.*, 774 F.3d at 603. The eHealth Defendants
2 challenge the sufficiency of Plaintiff’s allegations of material misrepresentations, scienter, and
3 loss causation.

4 **a. Material Misrepresentation or Omission**

5 For a statement to be actionable, it must be both false or misleading and material. Plaintiff
6 challenges as misleading statements made by Flanders and Yung during earnings calls held on
7 April 26, 2018, and February 20, 2020.

8 The Q1 2018 earnings call held on April 26, 2018, included the following exchange:

9 [Financial analyst:] So I wanted to walk through the commission
10 receivables. So if I look at the combination of your short and your
11 long-term receivables, even relative to your enterprise value, it’s
12 basically equivalent. So effectively that represents receivables that
13 you will be ultimately -- you will be receiving cash for under that
14 constrained assumption. Are there any other real costs associated
15 against that?

16 ...

17 [Flanders:] No, the costs attached to each of the receivable
18 balances have essentially been absorbed as we generate the
19 revenue in any particular quarter. *So as the cash comes in, there is
20 no additional cost attached to that. And the reason that those
21 receivables are there is because there is no meaningful service
22 component attached to them either.* So according to our contracts
23 with the carriers, these are all cash collection expectations that we
24 have, both in the short term and long term.

25 ECF No. 46 ¶ 75.³ Plaintiff alleges that the challenged statements were misleading because they
26 “left investors with the false impression that the commission receivables reported by eHealth had
27 no associated costs.” *Id.* ¶ 76. Plaintiff further avers that, “[c]ontrary to Flanders’ statement,
28 eHealth has additional operating expenses that it must incur in order to retain customers and keep
29 them from cancelling their policies within the first year,” *id.*, which included the cost of providing
30 “customer care service,” *id.* ¶ 71. These operating costs must be offset against any commissions
31 receivable. *Id.* ¶¶ 30-33.

32 The Q4 2019 earnings call held on February 20, 2020, included the following exchange:

33 _____
34 ³ Only the emphasized statements are challenged as misleading.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

[Financial analyst:] Okay. The final question would be, I know you highlighted the substantial growth in your commission receivable, both current and noncurrent. Can you talk about—and I know you mentioned some of this in your prepared remarks, can you talk about the expense associated with that receivable? Maybe the biggest piece would be the noncurrent. Is there any expense associated with that? Or is that pure, pure cash?

[Yung:] So the commission receivable represents the cash collections to be collected associated with the commissions that we earn from carriers for the policies that we help acquire customers for them on their behalf. So once that’s happened, and it’s actually the reason why we recognize the revenue we do, our service obligation is completed, and therefore, we recognize the lifetime value of that. *From an operating perspective, other than reconciling the cash coming in and the cash that we should be being paid as a broker record, there’s no other cost associated.*

[Flanders:] There’s no cost against it, Greg. It’s all—the costs have been expensed in period. *And it’s all cash to be collected free of additional charge.*

ECF No. 46 ¶ 91. Plaintiff alleges that these statements were misleading because they created the false impression that eHealth did not have any operating expenses that would need to be offset against the commissions it received from insurers. *Id.* ¶¶ 69-72, 92-93. Plaintiff alleges that eHealth had to incur operational costs associated with those commissions, including retention-related customer care expenses. *Id.* ¶¶ 30-31, 43.

The Court previously declined to dismiss these statements, holding that the allegations of the amended complaint were sufficient to raise the reasonable inference that a reasonable investor could have been misled into believing that eHealth did not have to incur any costs that had to be offset against the commissions it expected to receive from insurance companies. ECF No. 64 at 15, 17. Though Defendants argued operation expenses were irrelevant to recognition of revenue under ASC 606, the Court explained that nothing before it permitted the inference that these statements were made “in the context of the mechanics of revenue recognition under ASC 606.” *Id.* at 15, 17. Though Defendants argued eHealth adequately disclosed its operational expenses in SEC filings throughout the Class Period, that “d[id] not mean that the statements at issue, which were made *during an earnings call* and without any reference to any SEC filings in which Defendants disclosed operational expenses, could not have created ‘an impression of a state of affairs that differs in a material way from the one that actually exists.’” *Id.* at 16 (emphasis in

1 original) (quoting *Brody v. Transitional Hosps. Corp.*, 280 F.3d 997, 1006 (9th Cir. 2002)); *see id.*
 2 at 17 (rejecting Defendants’ arguments “for the same reasons discussed above in connection with
 3 the challenged statements made in the earnings call of April 26, 2018”).

4 Defendants now move for judgment on the pleadings, arguing that the challenged
 5 statements were not misleading as a matter of law. In the Ninth Circuit, courts “apply the
 6 objective standard of a ‘reasonable investor’ to determine whether a statement is misleading.” *In*
 7 *re Alphabet, Inc. Sec. Litig.*, 1 F.4th 687, 699 (9th Cir. 2021). “Section 10(b) and Rule 10b-5 . . .
 8 require disclosure ‘only when necessary ‘to make . . . statements made, in light of the
 9 circumstances under which they were made, not misleading.’” *Id.* (quoting *Matrixx Initiatives,*
 10 *Inc. v. Siracusano*, 563 U.S. 27, 44 (2011)). A statement is misleading “if it would give a
 11 reasonable investor the ‘impression of a state of affairs that differs in a material way from the one
 12 that actually exists.’” *Berson v. Applied Signal Tech., Inc.*, 527 F.3d 982, 985 (9th Cir. 2008)
 13 (quoting *Brody*, 280 F.3d at 1006).

14 Defendants argue that the challenged statements were not misleading because, considered
 15 in the context of the two earnings calls, the statements “were made from an accounting
 16 perspective.” ECF No. 117 at 16-19. The challenged statements from the Q1 2018 earnings call
 17 were made during the unscripted question-and-answer portion of the call, in response to an
 18 analyst’s question about commission receivables. ECF No. 117-1 at 15 (“So as the cash comes in,
 19 there is no additional cost attached to that. And the reason that those receivables are there is
 20 because there is no meaningful service component attached to them either.”). Defendants suggest
 21 that, because the prepared remarks delivered at the start of the call referenced the ASC 606
 22 revenue recognition accounting standard and the analyst used the term “constrained assumption,”
 23 the challenged statements concerned the mechanics of revenue recognition under ASC 606. ECF
 24 No. 117 at 18. Defendants similarly argue that the challenged statements from the Q4 2019 call
 25 were made in the context of revenue recognition under ASC 606, pointing to the speakers’ use of
 26 accounting terminology like “commission receivable,” revenue recognition, service obligation,
 27 and lifetime value. *Id.*

28 The Court is not persuaded that the challenged statements were not misleading in context.

1 The prior reference to ASC 606 during the Q1 2018 earnings call does not necessarily place the
2 entire call within the context of that accounting standard; this was a quarterly earnings call, and
3 the transcript reflects that many topics were discussed. The reference to “constrained assumption”
4 does not mandate the inference that the analyst’s question was about corresponding cost
5 accounts—rather than corresponding actual costs—and the Court cannot infer that a reasonable
6 investor would necessarily understand it as such. The language used by eHealth officers during
7 the Q4 2019 earnings call similarly does not establish that a reasonable investor would not be
8 misled by the officers’ statements that “[f]rom an operating perspective . . . there’s no other cost
9 associated” with the commission receivable and that “it’s all cash to be collected free of additional
10 charge.” ECF No. 117-1 at 69. Construing all reasonable inferences in Plaintiff’s favor, as the
11 Court must, the Court cannot conclude that the challenged statements made on the earnings calls
12 were not misleading as a matter of law.

13 Defendants argue that any misleading statements were not material because Defendants
14 disclosed the existence of customer care-related operational expenses during the relevant earnings
15 calls and in SEC filings referenced on those calls. Defendants are correct that both calls featured
16 generic references to operating expenses, including customer care and enrollment costs. But
17 Defendants do not point to any reference to specific operating costs associated with retaining
18 enrolled members—that is, any disclosure that establishes that the commission receivables had
19 associated operating costs. As the Court explained in its prior order, Plaintiff’s allegations are
20 sufficient to raise the reasonable inference that a reasonable investor could have been misled into
21 believing that eHealth did not have to incur any costs that had to be offset against the commissions
22 it expected to receive from insurance companies. Nothing in the transcript of either call addresses
23 that specific issue. “Where . . . reasonable minds could differ as to the adequacy of . . . disclosure
24 . . . , the question of whether that disclosure was adequate to render the challenged statements not
25 misleading cannot be resolved as a matter of law.” *In re Splunk Inc. Sec. Litig.*, 592 F. Supp. 3d
26 919, 940 (N.D. Cal. Mar. 21, 2022); *see also Fecht v. Price Co.*, 70 F.3d 1078, 1081 (9th Cir.
27 1995) (“[O]nly if the adequacy of the disclosure . . . is ‘so obvious that reasonable minds could not
28 differ’ are these issues ‘appropriately resolved as a matter of law.’” (quoting *Durning v. First Bos.*

1 *Corp.*, 815 F.2d 1265, 1268 (9th Cir. 1987)). Because the adequacy of the disclosures Defendants
2 identify is not obvious, such adequacy cannot be resolved as a matter of law.

3 Defendants’ argument concerning disclosure in SEC filings generally referenced during
4 both calls fails for the same reasons. On each call, investors were referred to documents,
5 including press releases, filed with the SEC that day. But Defendants identify nothing in those
6 SEC filings which specifically addresses the existence of post-enrollment, retention-related
7 operating costs, such that reasonable minds could not differ as to the adequacy of such disclosure.
8 As such, the adequacy of these disclosures cannot be resolved as a matter of law.

9 Finally, Defendants argue that Plaintiff fails to sufficiently plead materiality. A misleading
10 statement is only actionable if it is also material, meaning there is a “substantial likelihood that the
11 disclosure of the omitted fact would have been viewed by the reasonable investor as having
12 significantly altered the ‘total mix’ of information made available.” *TSC Indus., Inc. v. Northway,*
13 *Inc.*, 426 U.S. 438, 449 (1976). “The inquiry into materiality is ‘fact-specific.’” *Alphabet*, 1 F.
14 4th at 700 (quoting *Matrixx*, 563 U.S. at 43). As such, “resolving materiality as a matter of law is
15 generally appropriate ‘only if . . . the materiality of the statement is so obvious that reasonable
16 minds could not differ.’” *Id.* (quoting *Fecht*, 70 F.3d at 1081).

17 Where a reasonable investor believes there to be no additional costs associated with certain
18 revenue—that it is, as Defendants stated, “cash to be collected free of additional charge,” ECF
19 No. 117-1 at 69—it is reasonable to infer that the fact that additional costs *must* be incurred to
20 ensure receipt of that revenue would be viewed by a reasonable investor as significantly altering
21 the total mix of available information. Plaintiff’s allegations, taken as true, raise the reasonable
22 inference that such investor would view disclosure of the fact that there *were* post-enrollment
23 expenses associated with the commission as significantly altering the total mix of information
24 available. Taking the facts alleged in the complaint as true and construing all reasonable
25 inferences Plaintiff’s favor, Plaintiff has sufficiently alleged the materiality of the challenged
26 statements.

27 ///

28 ///

b. Scierter

1 Defendant argues that Plaintiff fails to sufficiently plead scierter. To establish scierter, the
2 complaint must “state with particularity facts giving rise to a strong inference that the defendant
3 acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2)(A). The required state of mind is
4 “a mental state that not only covers ‘intent to deceive, manipulate, or defraud,’ but also ‘deliberate
5 recklessness[.]’” *Schueneman v. Arena Pharms., Inc.*, 840 F.3d 698, 705 (9th Cir. 2016) (internal
6 citation omitted). Deliberate recklessness is ““an extreme departure from the standards of ordinary
7 care,’ which ‘presents a danger of misleading buyers or sellers that is either known to the
8 defendant or is so obvious that the actor must have been aware of it.”” *Alphabet*, 1 F. 4th at 701
9 (emphasis omitted) (quoting *Nguyen v. Endologix, Inc.*, 962 F.3d 405, 414 (9th Cir. 2020)).
10 “Facts showing mere recklessness or a motive to commit fraud and opportunity to do so provide
11 some reasonable inference of intent, but are not sufficient to establish a strong inference of
12 deliberate recklessness.” *In re VeriFone Holdings, Inc. Sec. Litig.*, 704 F.3d 694, 701 (9th Cir.
13 2012).

14 The “strong inference” required by the PSLRA “must be more than merely ‘reasonable’ or
15 ‘permissible’—it must be cogent and compelling, thus strong in light of other explanations.”
16 *Tellabs*, 551 U.S. at 324. “A court must compare the malicious and innocent references
17 cognizable from the facts pled in the complaint, and only allow the complaint to survive a motion
18 to dismiss if the malicious inference is at least as compelling as any opposing innocent inference.”
19 *Zucco Partners, LLC v. Digimarc Corp.*, 552 F.3d 981, 991 (9th Cir. 2009). In evaluating whether
20 a complaint satisfies the “strong inference” requirement, courts must consider the allegations and
21 other relevant material “holistically,” not “scrutinized in isolation.” *VeriFone*, 704 F.3d at 701-02.

22 The Court previously held that Plaintiff’s allegations, “considered holistically, raise the
23 reasonable inference that individual Defendants acted with at least deliberate recklessness when
24 making the April 26, 2018[] and February 20, 2020[] challenged statements, which . . . created the
25 false impression that eHealth did not have operational expended that [would] need[] to be offset
26 against its commissions receivable.” ECF No. 64 at 19. The Court found that, “[b]ecause of the
27 magnitude of the operational expenses at issue, the amended complaint raises the inference that
28

1 the individual Defendants, who allegedly participated in eHealth’s management and operations at
2 the highest level by virtue of being the company’s CEO, CFO, and COO, were aware of them and
3 the importance of disclosing them to investors,” and that their “failure to mention or acknowledge
4 operational expenses [associated with post-enrollment retention] when making the challenged
5 statements created an obvious danger of misleading investors.” *Id.* at 19-20. The Court further
6 noted that additional allegations, including those concerning Defendants’ compensation-related
7 motive to inflate eHealth’s stock price, supported a finding of scienter. *Id.* at 20 n.5.

8 For the reasons outlined in its prior order, the Court again concludes that Plaintiff’s
9 allegations, considered holistically, raise a strong inference of deliberate recklessness. While
10 Defendants argue that the “far more plausible inference is that Defendants honestly believed they
11 were discussing such expenses from the accounting perspective of ASC 606,” ECF No. 117 at 21,
12 the Court finds that, considered as a whole, Plaintiff’s allegations raise a strong inference of
13 deliberate recklessness that is “at least as compelling” as any “opposing innocent inference.”
14 *Zucco*, 552 F.3d at 991. Taking Plaintiff’s allegations as true, it is implausible that Defendants did
15 not know that there were post-enrollment retention costs associated with the commissions
16 receivable or were unaware that describing such commissions as “all cash to be collected free of
17 additional charge,” with “no other cost associated” and “no meaningful service component
18 attached” created an obvious danger of misleading investors. ECF No. 46 ¶¶ 75, 91.

19 Plaintiff sufficiently pleads scienter as to the remaining challenged statements.

20 **c. Loss Causation**

21 Defendant argues that Plaintiff fails to sufficiently plead loss causation. To establish loss
22 causation, the plaintiff must prove “that the act or omission of the defendant alleged to violate
23 th[e] [Exchange Act] caused the loss for which the plaintiff seeks to recover damages.” 15 U.S.C.
24 § 78u-4(b)(4). “Because loss causation is simply a variant of proximate cause, the ultimate issue
25 is whether the defendant’s misstatement, as opposed to some other fact, foreseeably caused the
26 plaintiff’s loss.” *Lloyd v. CVB Fin. Corp.*, 811 F.3d 1200, 1210 (9th Cir. 2016) (internal citation
27 omitted). “[T]o prove loss causation by relying on one or more corrective disclosures, a plaintiff
28 must show that (1) a corrective disclosure revealed, in whole or in part, the truth concealed by the

1 defendant’s misstatements; and (2) disclosure of the truth caused the company’s stock price to
 2 decline and the inflation attributable to the misstatements to dissipate.” *In re BofI Holding, Inc.*
 3 *Sec. Litig.*, 977 F.3d 781, 791 (9th Cir. 2020). “At the pleading stage, the plaintiff’s task is to
 4 allege with particularity facts ‘plausibly suggesting’ that both showings can be made.” *Id.*
 5 (quoting *Bell Atlantic Corp. v. Twombly*, 550 U.S. 554, 557 (2007)).

6 Plaintiff alleges that the challenged statements artificially inflated the price of eHealth
 7 stock, which dropped after two corrective disclosures revealed the truth of the company’s financial
 8 situation. First, following the April 8, 2020 publication of the Muddy Waters Capital report, the
 9 stock price dropped from \$136.32 to \$103.20 per share. ECF No. 46 ¶¶ 6, 48, 57. Second, after
 10 eHealth announced its Q2 2020 earnings results, the stock price dropped further, to \$79.17 per
 11 share. *Id.* ¶ 7.

12 Defendants argue that the Muddy Waters report cannot constitute a corrective disclosure,
 13 citing *BofI*, 977 F.3d at 797. In *BofI*, the Ninth Circuit outlined “a flexible approach to evaluating
 14 corrective disclosures,” under which courts ask whether, “[b]ased on plaintiffs’ particularized
 15 allegations, [they] can [] plausibly infer that the alleged corrective disclosure provided new
 16 information to the market that was not yet reflected in the company’s stock price.” *Id.* at 795.
 17 Factors to consider include whether the underlying data was publicly available, the complexity of
 18 the data and its relationship to the alleged misstatements, and the great effort needed to locate and
 19 analyze it. *Id.* Applying this approach, the Ninth Circuit concluded that shareholders had not
 20 plausibly alleged that blog posts based on publicly available information constituted corrective
 21 disclosures because “the posts were authored by anonymous short-sellers who had a financial
 22 incentive to convince others to sell, and the posts included disclaimers from the authors,” such that
 23 “[a] reasonable investor . . . would likely have taken their contents with a healthy grain of salt.”
 24 *Id.* at 797; *see also Grigsby v. BofI Holding, Inc.*, 979 F.3d 1198, 1208 (9th Cir. 2020) (holding
 25 that article could not constitute corrective disclosure where it was written by an anonymous short-
 26 seller, was based on publicly available information, did not require expertise beyond that of a
 27 typical market participant, and included a disclaimer about its accuracy and completeness); *In re*
 28 *Nektar Therapeutics Sec. Litig.*, 34 F.4th 828, 840 (9th Cir. 2022) (holding that report could not

1 constitute corrective disclosure where it was written by anonymous short-sellers who disclaimed
2 the accuracy or completeness of the information provided). “*Bofl* underscored the high bar that
3 plaintiffs must meet in relying on self-interested and anonymous short-sellers.” *Nektar*, 34 F.4th
4 at 839.

5 The Muddy Waters report is not a corrective disclosure under *Bofl* and related cases.
6 Muddy Waters is a short-seller with a financial incentive to convince others to sell: the first page
7 of the Muddy Waters report warns readers that they “should assume that . . . [Muddy Waters] ha[s]
8 a short position in one or more of the securities of a Covered Issuer . . . and therefore stand[s] to
9 realize significant gains in the event that the prices of either equity or debt securities of a Covered
10 Issuer decline or appreciate.” ECF No. 117-1 at 114. The report warns that all information “is
11 presented ‘as is,’ without warranty of any kind, whether express or implied,” and that Muddy
12 Waters “makes no representation, express or implied, as to the accuracy, timeliness, or
13 completeness of any such information.” *Id.* The report has no identified author and appears to
14 contain only public information. In light of *Bofl* and related cases, Plaintiff fails to plausibly
15 allege that the Muddy Waters report constitutes a corrective disclosure.

16 Defendant further argues that Plaintiff fails to allege that the Q2 2020 earnings results
17 announcement revealed the allegedly concealed post-enrollment customer care costs associated
18 with retention. Plaintiff alleges that the Muddy Waters report disclosed that eHealth “pretends
19 that ongoing service needs, which carry real costs, do not exist,” ECF No. 36 ¶ 57, and that the Q2
20 2020 earnings results “confirmed these concerns,” *id.* ¶ 64. Plaintiff alleges that, on the Q2 2020
21 earnings call, Flanders stated that eHealth was “making a strategic decision to increase [its] focus
22 on member retention and recapture.” *Id.* ¶ 64. None of Plaintiff’s remaining allegations about the
23 Q2 2020 earnings results address post-enrollment customer care costs.

24 Plaintiff does not sufficiently allege that the Q2 2020 earnings results constitute a
25 corrective disclosure because Plaintiff does not allege that those results “revealed, in whole or in
26 part, the truth concealed by the defendant’s misstatements.” *Bofl*, 977 F.3d at 791. Taken as true,
27 the facts alleged in the complaint do not support a reasonable inference that the Q2 2020 earnings
28 results revealed that eHealth had concealed post-enrollment, retention-related customer care costs.

1 And Flanders’s statement is not plausibly understood as an admission of past concealment of
2 retention-related costs, but rather as a forward-looking statement of intent to increase spending on
3 retention.

4 Because Plaintiff fails to sufficiently plead loss causation, Plaintiff’s Section 10(b) claims
5 against the eHealth Defendants must be dismissed.

6 **2. Section 20(a) Claims**

7 Because Plaintiff fails to plead a predicate violation of securities law, Plaintiff’s Section
8 20(a) claims against the eHealth Defendants necessarily fail. *In re NVIDIA Corp. Sec. Litig.*, 768
9 F.3d 1046, 1052 (9th Cir. 2014) (“To establish a cause of action under [Section 20(a)], a plaintiff
10 must first prove a primary violation of underlying federal securities laws, such as Section 10(b) or
11 Rule 10b-5, and then show that the defendant exercised actual power over the primary violator.”).

12 **3. Leave to Amend**

13 Plaintiff requests leave to amend, which Defendants do not oppose. “[A]lthough Rule
14 12(c) does not mention leave to amend, courts have discretion both to grant a Rule 12(c) motion
15 with leave to amend, and to simply grant dismissal of the action instead of entry of judgment.”
16 *Sarmiento v. Sealy*, 367 F. Supp. 3d 1131, 1139 (N.D. Cal. 2019) (quoting *Lonberg v. City of*
17 *Riverside*, 300 F. Supp. 2d 942, 945 (C.D. Cal. 2004)). “[A] district court should grant leave to
18 amend even if no request to amend the pleading was made, unless it determines that the pleading
19 could not possibly be cured by the allegation of other facts.” *Doe v. United States*, 58 F.3d 494,
20 497 (9th Cir. 1995) (quoting *Cook, Perkiss & Liehe v. N. Cal. Collection Serv.*, 911 F.2d 242, 247
21 (9th Cir. 1990)); see *Harris v. Cnty. of Orange*, 682 F.3d 1126, 1131-34 (9th Cir. 2012) (affirming
22 dismissal under Rule 12(c) but reversing for failure to grant leave to amend).

23 Plaintiff’s Section 10(b) claims against the eHealth Defendants must be dismissed for
24 failure to sufficiently plead loss causation. Plaintiff’s Section 20(a) claims against these
25 Defendants must be dismissed for failure to establish predicate securities violations. Because the
26 allegation of additional facts could cure Plaintiff’s failure to establish loss causation, the Court
27 will grant leave to amend Plaintiff’s Section 10(b) and 20(a) claims against eHealth, Yung, and
28 Flanders.

1 **B. Francis’s Motion for Judgment on the Pleadings**

2 Francis moves for judgment on the pleadings, arguing that Plaintiff’s claims against him
3 fail as a matter of law.

4 **1. Section 10(b) and Rule 10b-5 Claim**

5 Francis argues that Plaintiff cannot state a Section 10(b) claim against him because he did
6 not make any of the remaining statements. In the securities context, “the maker of a statement is
7 the person or entity with ultimate authority over the statement, including its content and whether
8 and how to communicate it.” *Janus Cap. Grp., Inc. v. First Derivative Traders*, 564 U.S. 135, 142
9 (2011). “One ‘makes’ a statement by stating it. . . . Even when a speechwriter drafts a speech, the
10 content is entirely within the control of the person who delivers it. And it is the speaker who takes
11 credit—or blame—for what is ultimately said.” *Id.* at 142-43.

12 The allegedly misleading statements were delivered aloud by Flanders and Yung during
13 the question-and-answer portions of two earnings calls. These were not remarks prepared in
14 advance, but rather extemporaneous responses to analysts’ questions. Francis did not deliver any
15 of the challenged statements, and therefore is not liable for making these statements. *See City of*
16 *Royal Oak Ret. Sys. v. Juniper Networks, Inc.*, 800 F. Supp. 2d 1045, 1071 (N.D. Cal. 2012)
17 (dismissing claims based on misleading statements of other defendants on analyst or investor
18 calls); *In re Coinstar Inc. Sec. Litig.*, No. C11-133 MJP, 2011 WL 4712206, at *10 (W.D. Wash.
19 Oct. 6, 2011) (dismissing claims based on misleading statements of other executives at
20 conferences).

21 Plaintiff argues that there is a dispute of fact about whether Francis had “‘ultimate
22 authority’ over the Company’s message about its operating costs.” ECF No. 125 at 15. Plaintiff
23 alleges that Francis controlled the contents of SEC filings, press releases, and other publicly
24 available documents, ECF No. 46 ¶ 17, and suggests that Francis was in a position to inform the
25 market about the allegedly concealed post-enrollment retention costs. However, given the nature
26 of the remaining challenged statements in this case, Francis cannot have had “ultimate authority”
27 over them. As the Supreme Court explained, regardless of who drafts the message, the speaker
28 retains ultimate authority over the spoken statement, because they control the actual content of the

1 statement and whether and how their message is communicated. *Janus*, 564 U.S. at 142-43.
2 Under *Janus*, Francis cannot have exercised ultimate authority over the extemporaneous oral
3 statements of other corporate officers.

4 Because Francis did not “make” the remaining challenged statements under *Janus*, the
5 Section 10(b) claims against him based on these statements must be dismissed.

6 **2. Section 20(a) Claim**

7 Absent a predicate violation of securities law, Plaintiff’s Section 20(a) claim against
8 Francis also fails. *NVIDIA*, 768 F.3d at 1052.⁴

9 **3. Leave to Amend**

10 “Dismissal without leave to amend is appropriate only when the Court is satisfied that an
11 amendment could not cure the deficiency.” *Harris*, 682 F.3d at 1135. Because Plaintiff’s Section
12 10(b) claim against Francis cannot be cured by allegation of additional facts, and Plaintiff cannot
13 plead a Section 20(a) claim against Francis in the absence of a predicate securities violation, the
14 Court denies leave to amend these claims.

15 **CONCLUSION**

16 Plaintiff’s claims against eHealth, Yung, and Flanders are dismissed with leave to amend.
17 Leave to amend is granted solely to cure the deficiencies identified above. Any amended
18 complaint shall be filed within 28 days of this order.

19 Plaintiff’s claims against Francis are dismissed with prejudice.

20 **IT IS SO ORDERED.**

21 Dated: September 28, 2023

22 
23 _____
24 JON S. TIGAR
25 United States District Judge

26
27
28 ⁴ Because Plaintiff fails to sufficiently plead a primary violation, the Court does not reach Francis’s argument concerning actual power.